QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio

Author's Avatar
May 03, 2023

Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.47 CER // 12% CER sales growth in non-COVID product portfolio to $434 million, while COVID product sales decline 76% to $52 million // Full-year 2023 outlook reaffirmed for at least $2.05 billion net sales CER, led by double-digit CER growth in non-COVID products; adj. diluted EPS of at least $2.10 CER